UNASSIGNED: Left ventricular ejection fraction (LV-EF), despite its high feasibility, is not sensitive enough to detect early and @entity299 during oncologic treatments. Therefore, we used @entity299 (GLS) by speckle tracking echocardiography to verify whether early @entity299 induced by adjuvant therapy in early @entity0 @entity1 at low risk for @entity1370 can be reversed. Thirty @entity1 (aged 53    11 y) with no previous @entity299 who were receiving adjuvant trastuzumab and @entity3907 (group @entity1722 +, n  = 15) or @entity3907 only (group @entity1722 -, n  = 15), after treatment with @entity8253 , were studied. LV-EF and GLS were measured at baseline, after @entity8253 (end of week 7 or 8), short term after trastuzumab and/or @entity3907 (end of week 18) and after completion of therapy. Significant @entity299 was defined as a relative reduction in GLS of >10% with respect to baseline values. Mean and individual LV-EFs did not change significantly during the oncologic treatment and after completion of therapy, although GLS varied significantly. In particular, during the course of therapy, four @entity1 in the trastuzumab- @entity1205 @entity1722 + subgroup and two @entity1 in the @entity3907 @entity1722 - subgroup had a relative decrease (>10%) in GLS. However, after the end of adjuvant treatment, strain modification was fully or partially reversible. Speckle tracking echocardiography is more sensitive than LV-EF in recognizing subtle @entity296 during adjuvant chemotherapy. However, in @entity1 at low risk for @entity1370 , these alterations may be reversible and not associated with clinically significant @entity1370 or late development of decreased LV-EF.

Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial impairment'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity8253 :: ('MESH:D018943', 'Chemical') :: ['anthracyclines'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity3907 :: ('MESH:C080625', 'Chemical') :: ['taxane'] @entity299 :: ('MESH:D006331', 'Disease') :: ['LV systolic dysfunction', 'cardiac and oncologic disease', 'subtle LV systolic dysfunction', 'systolic global longitudinal strain'] @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiotoxicity'] @entity1722 :: ('2064', 'Gene') :: ['HER2']
@entity1 :: (9606,Species) :: ['Patients']
